<DOC>
	<DOCNO>NCT01360255</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) one tumor increase incidence worldwide . Often treatment possibility limit palliative treatment transarterial chemoembolisation ( TACE ) possible . Therapeutic response evaluate three month TACE image technique ( CT , MRI ) . In HCC patient tumor marker AFP ( alpha-fetoprotein ) elevate , patient show elevation . In last year new tumor marker AFP-L3 ( subfraction AFP ) des-y-carboxyprothrombin ( DCP ) examine . In clinical trial course marker examine TACE order receive hint patient therapeutic responder . Furthermore investigator interested quality life TACE . Patients receive questionnaire regard quality life 3 month TACE .</brief_summary>
	<brief_title>AFP- L3 % DCP Tumor Markers Patients With Hepatocellular Carcinoma ( HCC ) Treated With Transarterial Chemoembolisation ( TACE )</brief_title>
	<detailed_description>Patients hepatocellular carcinoma ( HCC ) treat transarterial chemoembolisation enrol clinical trial . The aim trial evaluate usefulness liver cancer marker AFP , AFP-L3 % ( subfraction AFP ) des-y- carboxyprothrombin ( DCP ) TACE therapy . Some author could show AFP-L3 % rise small tumor nodule 2 cm marker decrease TACE give hint therapeutic response intervention . So important aim trial improve early detection tumor recurrence TACE . Furthermore quality life measure EORTC QLQ C30 TACE evaluate .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>age 18 80 diagnosis HCC accord AASLD criterion TACE plan resection impossible liver tumor unknown origin liver tumor TACE impossible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>transarterial chemoembolisation</keyword>
	<keyword>liver cancer marker : AFP , AFP-L3 % DCP</keyword>
</DOC>